Unknown

Dataset Information

0

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management.


ABSTRACT: Epilepsy, a common multifactorial neurological disease, affects about 69 million people worldwide constituting nearly 1% of the world population. Despite decades of extensive research on understanding its underlying mechanism and developing the pharmacological treatment, very little is known about the biological alterations leading to epileptogenesis. Due to this gap, the currently available antiepileptic drug therapy is symptomatic in nature and is ineffective in 30% of the cases. Mounting evidences revealed the pathophysiological role of neuroinflammation in epilepsy which has shifted the focus of epilepsy researchers towards the development of neuroinflammation-targeted therapeutics for epilepsy management. Markedly increased expression of key inflammatory mediators in the brain and blood-brain barrier may affect neuronal function and excitability and thus may increase seizure susceptibility in preclinical and clinical settings. Cyclooxygenase-2 (COX-2), an enzyme synthesizing the proinflammatory mediators, prostaglandins, has widely been reported to be induced during seizures and is considered to be a potential neurotherapeutic target for epilepsy management. However, the efficacy of such therapy involving COX-2 inhibition depends on various factors viz., therapeutic dose, time of administration, treatment duration, and selectivity of COX-2 inhibitors. This article reviews the preclinical and clinical evidences supporting the role of COX-2 in seizure-associated neuroinflammation in epilepsy and the potential clinical use of COX-2 inhibitors as a future strategy for epilepsy treatment.

SUBMITTER: Rawat C 

PROVIDER: S-EPMC6822425 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management.

Rawat Chitra C   Kukal Samiksha S   Dahiya Ujjwal Ranjan UR   Kukreti Ritushree R  

Journal of neuroinflammation 20191030 1


Epilepsy, a common multifactorial neurological disease, affects about 69 million people worldwide constituting nearly 1% of the world population. Despite decades of extensive research on understanding its underlying mechanism and developing the pharmacological treatment, very little is known about the biological alterations leading to epileptogenesis. Due to this gap, the currently available antiepileptic drug therapy is symptomatic in nature and is ineffective in 30% of the cases. Mounting evid  ...[more]

Similar Datasets

| S-EPMC6738329 | biostudies-literature
| S-EPMC5679100 | biostudies-literature
| S-EPMC3978385 | biostudies-literature
| S-EPMC3408963 | biostudies-literature
| S-EPMC7056757 | biostudies-literature
| S-EPMC4514697 | biostudies-other
| S-EPMC6603181 | biostudies-literature
| S-EPMC3956447 | biostudies-literature
| S-EPMC10094968 | biostudies-literature